NO20045343L - Ny kombinasjon for behandling av luftveisforstyrrelser - Google Patents

Ny kombinasjon for behandling av luftveisforstyrrelser

Info

Publication number
NO20045343L
NO20045343L NO20045343A NO20045343A NO20045343L NO 20045343 L NO20045343 L NO 20045343L NO 20045343 A NO20045343 A NO 20045343A NO 20045343 A NO20045343 A NO 20045343A NO 20045343 L NO20045343 L NO 20045343L
Authority
NO
Norway
Prior art keywords
treatment
respiratory disorders
new combination
respiratory
combination
Prior art date
Application number
NO20045343A
Other languages
English (en)
Norwegian (no)
Inventor
Stefan Postius
Wolfgang-Alexander Simon
Guido Hanauer
Wolfgang Kromer
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of NO20045343L publication Critical patent/NO20045343L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20045343A 2002-05-07 2004-12-06 Ny kombinasjon for behandling av luftveisforstyrrelser NO20045343L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010305 2002-05-07
PCT/EP2003/004653 WO2003094967A2 (en) 2002-05-07 2003-05-03 New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders

Publications (1)

Publication Number Publication Date
NO20045343L true NO20045343L (no) 2004-12-06

Family

ID=29414673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045343A NO20045343L (no) 2002-05-07 2004-12-06 Ny kombinasjon for behandling av luftveisforstyrrelser

Country Status (17)

Country Link
US (1) US20050222193A1 (es)
EP (1) EP1506016A2 (es)
JP (1) JP2005528418A (es)
KR (1) KR20050007476A (es)
CN (1) CN1652822A (es)
AU (1) AU2003227710A1 (es)
BR (1) BR0309808A (es)
CA (1) CA2484272A1 (es)
EA (1) EA200401454A1 (es)
HR (1) HRP20041160A2 (es)
IL (1) IL164755A0 (es)
MX (1) MXPA04011018A (es)
NO (1) NO20045343L (es)
PL (1) PL373287A1 (es)
RS (1) RS95304A (es)
WO (1) WO2003094967A2 (es)
ZA (1) ZA200407896B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453493A2 (en) * 2001-11-19 2004-09-08 ALTANA Pharma AG Reversible proton pump inhibitors for the treatment of airway disorders
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
AU2005237246A1 (en) * 2004-04-30 2005-11-10 Nycomed Gmbh Method of classifying GERD
CA2582300A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
CA2997471C (en) 2010-11-16 2020-12-01 Texas Heart Institute Agonists that enhance binding of integrin-expressing cells to integrin receptors
KR101873530B1 (ko) * 2012-04-10 2018-07-02 삼성전자주식회사 모바일 기기, 모바일 기기의 입력 처리 방법, 및 모바일 기기를 이용한 전자 결제 방법
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
SI0706513T1 (en) * 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
DE19541689A1 (de) * 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
NZ298853A (en) * 1995-01-27 1998-07-28 Rhone Poulenc Rorer Ltd 5-[2-cyano-phenoxy]-2-phenyl-acetic acid derivatives
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
EP0852498A1 (en) * 1995-09-26 1998-07-15 Takeda Chemical Industries, Ltd. Phosphorylamides, their preparation and use
US6599927B2 (en) * 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
SE9603725D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New teatment
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
AU9067198A (en) * 1997-07-25 1999-02-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
US6060472A (en) * 1998-04-06 2000-05-09 Apotex Inc. Thiadiazole compounds useful as inhibitors of H+ /K+ atpase
JP2002523452A (ja) * 1998-08-26 2002-07-30 スミスクライン・ビーチャム・コーポレイション 肺疾患の治療方法
DE69905178T2 (de) * 1998-09-23 2003-07-17 Altana Pharma Ag Tetrahydropyridoether
GB9911017D0 (en) * 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
NZ520837A (en) * 2000-03-29 2005-01-28 Altana Pharma Ag Prodrugs of imidazopyridine derivatives
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US6528527B2 (en) * 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
EP1453493A2 (en) * 2001-11-19 2004-09-08 ALTANA Pharma AG Reversible proton pump inhibitors for the treatment of airway disorders

Also Published As

Publication number Publication date
KR20050007476A (ko) 2005-01-18
WO2003094967A2 (en) 2003-11-20
IL164755A0 (en) 2005-12-18
US20050222193A1 (en) 2005-10-06
MXPA04011018A (es) 2005-01-25
HRP20041160A2 (en) 2005-08-31
PL373287A1 (en) 2005-08-22
AU2003227710A1 (en) 2003-11-11
BR0309808A (pt) 2005-03-01
JP2005528418A (ja) 2005-09-22
EA200401454A1 (ru) 2005-06-30
CN1652822A (zh) 2005-08-10
CA2484272A1 (en) 2003-11-20
RS95304A (en) 2006-12-15
ZA200407896B (en) 2006-06-28
WO2003094967A3 (en) 2004-04-01
EP1506016A2 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
DK1809280T3 (da) Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf
CY1118171T1 (el) Θεραπευτικη αντιμετωπιση της φαiνυλκετονουρiας me βη4
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
DE50310516D1 (de) Fredericamycin-derivate
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
DK1768490T3 (da) Systemer og fremgangsmåder til ex-vivo-organpleje
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
IS8071A (is) Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
ATE256672T1 (de) 4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
NO20075764L (no) Kombinert anvendelse av prostaglandinforbindelse og protonpumpeinhibitor til behandling av forstyrrelser i mage- og tarmkanalen
NO20052999L (no) Ny synergistisk kombinasjon omfattende roflumilast og formoterol
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
ATE410235T1 (de) Behandlung von ballastwasser
ATE415961T1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7- dimethylbicycloä2.2.1ühept-1- ylmethanesulphonamide-familie
DE60329326D1 (de) Tace inhibitoren
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
NO20045344L (no) Kombinasjon for behandling av luftveisforstyrrelser
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104